Pfizer (PFE)

[blid2def]

Pfizer in talks to buy Wyeth, deal could top $60 bln- WSJ

http://www.reuters.com/article/mergersN ... 1620090123

Jan 23 (Reuters) - Pfizer Inc (PFE.N) is in talks to buy rival drug maker Wyeth (WYE.N) in a deal that could be valued at more than $60 billion, the Wall Street Journal said, citing people familiar with the matter.

The two sides have been in discussions for months and a deal is not imminent, the people told the paper.

The talks are fragile given recent market volatility and weak global economic conditions, and could collapse, the people told the paper. (Reporting by Ajay Kamalakaran in Bangalore; Editing by Kim Coghill)

[winston]

Boycott Pfizer

At this point, you may be suffering from outrage fatigue.

If so, I've got just the thing for that: a good old-fashioned boycott.

Earlier this month I suggested that we all avoid purchasing products made by Pfizer.

Of course, this Big Pharma giant makes a number of insanely successful prescription drugs, including Lipitor, Viagra, Celebrex, Xanax, Zoloft, Chantix, and Enbrel.

Now, I know most of you don't take pharmaceuticals when you can avoid them. But Pfizer also produces quite a few over-the-counter drugs and non-drug products such as ChapStick, Advil, ThermaCare heat wraps, Anbesol oral pain reliever, Dristan, Robitussin, Preparation H, FiberCon, and the Centrum line of multivitamins.

So...why boycott? We'll start with an item I sent you last summer...

Billion-dollar shell game

It's not easy to become the Number One industry in the category of Defrauding the U.S. Government, but the drug industry managed to easily out-fraud every other commercial sector over the past 20 years.

And what company topped that list? Pfizer. They coughed up a settlement of more than $2 billion for one infraction -- illegal marketing of Bextra, their now-defunct painkiller.

Keep in mind that when the government is defrauded, your tax dollars are wasted. And that would be reason enough for a boycott. But then there's also this...

Getting off easy

When you find out the details about Pfizer's alleged illegal drug testing on children in Nigeria -- and the subsequent efforts to deny the testing and then cover it up -- you might never want to see the word "Pfizer" in your home again.

Bye bye, ChapStick! Adios, Advil! Farewell, FiberCon! (Oops...no pun intended.)

Source: HSI

[winston]

not vested

7 Cash-Rich Stocks to Buy: Pfizer (PFE)

Total Cash & Equivalents: $28 billion

Pharmaceutical giant Pfizer (PFE) does what most sensible, mature companies with tens of billions of dollars in the bank does: It pays a dividend (are you listening, Google?).

Having raised its dividend for five straight years, the PFE dividend yield now sits at 3.3%.

Of course, pharmaceutical companies like Pfizer need to constantly invest in drug discovery, so a healthy amount of cash on the books is more or less required for long-term success.

In 2014, PFE spent $8.31 billion (16.8% of revenues) on research & development, up dramatically from the $6.55 billion (12.7% of revenues) in 2013.

That increased focus on R&D, on top of the fact that PFE is one of the 10 Best Dow Dividend Stocks month after month, should have investors jazzed about how Pfizer is spending its money.

On top of that, Pfizer bought Hospira (HSP) — a generic drug company that develops biosimilars, — for $15.2 billion earlier this year.

Generics are some of the hottest acquisition targets in the stock market today, so if Pfizer didn’t get its hands on Hospira, it probably would’ve been snapped up by a competitor.

Source: Investor Place

[winston]

Cheap Dividend Stocks: Pfizer Inc. (PFE)

Dividend Yield: 4%

Pfizer Inc. (PFE) is about as uninspiring a stock as you can get these days, but the pharmaceutical giant has powerful long-term demographics at its back.

The youngest baby boomers are turning 52 this year. The oldest boomers turn 70. Demand for drugs is only going up.

At the same time, Pfizer’s dividend will boost total returns, and it has the potential to keep rising. Pfizer has raised its dividend every year for six years, and it pays out less than half of its earnings in dividends.

Most importantly, PFE is a cheap stock. At not quite 12 times forward earnings, PFE trades below its own long-term average. It’s also about 28% cheaper than the broader market, according to Thomson Reuters Stock Reports.

Source: Investor Place

[winston]

Pfizer Inc.: Why PFE Stock Isn’t as Wild as It Seems

Pfizer stock continues to be erratic, but there's a method to the madness for those looking to time a trade

By James Brumley

Source: Investor Place

http://investorplace.com/2016/05/pfe-pf ... yg61vl96M8

[winston]

not vested

Pfizer (NYSE: PFE) is one the world’s largest pharmaceutical firms, with nearly $50 billion in annual sales and the economies of scale to support a huge salesforce.

The company has worked through the bulk of its near-term patent expirations, with only Viagra coming off protection in 2017.

Pfizer is a cash machine, generating $13 billion in free cash and covering the dividend by 188% last year.

The company has scaled back its R&D spending which could drive cash flow even higher over the next couple of years.

Pfizer returned another $6.2 billion through its share buyback program in 2015, for a 2.9% yield beyond the 3.5% dividend yield.

Earnings are expected 2.5% higher to $2.50 per share over the next year, but the company has a strong history for beating expectations, missing only once in the last 16 quarters.

Shares fell from the 52-week high in August, representing a buying opportunity on the $38.25 per share target at 15-times forward earnings of $2.55 per share.

Source: Street Authority

[winston]

This Stock Seems Like a Good Consideration for Investors Living Off Dividends in Retirement

By Brian Bollinger

Source: Simply Safe Dividends

http://dailytradealert.com/2016/10/17/t ... etirement/

[winston]

not vested

Stocks to Buy for the Next Decade: Pfizer (PFE)

Investors would be forgiven for wanting to avoid the pharmaceutical industry altogether.

Political and regulatory risks abound, drugmakers have faced significant criticism about pricing practices over the past few years, leading to arguments in some quarters for price caps or importation of overseas products that could pressure margins.

But Pfizer Inc. (NYSE:PFE) likely is worth the risk. The world’s second-largest drugmaker, behind Novartis AG (ADR) (NYSE:NVS), isn’t growing the way it once did. But it is still growing, with EPS expected to increase roughly 7% this year and 8% in 2018.

But PFE stock isn’t really priced for any growth, with a 13x forward P/E multiple and a 3.5% dividend yield. And that seems just too conservative.

Pfizer isn’t going to be an explosive stock, but expecting 8-10% share price growth and a nice dividend doesn’t seem terribly outlandish at current prices.

With a broad and diversified portfolio providing some downside protection, PFE’s upside potential is worth dealing with potential political risk.

Source: Investor Place

[winston]

not vested

Pfizer

This top pharmaceutical stock made a gigantic splash in June with a $10.6 billion purchase of cancer drug maker Array BioPharma.

Pfizer Inc. (NYSE: PFE) is a global biopharmaceutical company with a diversified portfolio of products and pipeline candidates, and it is one of the largest pharmaceutical companies in the world as measured by market capitalization and revenue. It also is a component of the Dow Jones industrial average and has one of the highest paid CEOs in America.

The company’s commercial operations are bifurcated into two business segments:
1. Innovative Health, which focuses on the development and commercialization of medicines and vaccines, as well as consumer health care products, in various therapeutic areas, and
2. Essential Health, which offers branded generic products, biosimilars, anti-infectives and other products without marketing patent protection.

Pfizer pays out a very solid 4.01% dividend.

Credit Suisse rates the shares Buy with a price objective of $48.

The posted consensus price objective is $41.82, and the shares closed Friday’s trading at $36.22. The stock is down a stunning 17% so far this year.

Source: 24 / 7 Wall Street

[winston]

not vested

Undervalued Dividend Growth Stock of the Week: Pfizer (PFE)

by Jason Fieber

Bottom line: Pfizer Inc. (PFE) is a high-quality company with durable competitive advantages. With an exciting upcoming spin-off, a yield more than twice as high as the S&P 500, a modest payout ratio, strong dividend growth, and the potential that shares are 6% undervalued, this looks like a relatively attractive stock in an otherwise elevated market.

Source: Mr. Free at 33

https://dailytradealert.com/2020/01/19/ ... fizer-pfe/